Androgen deprivation therapy may promote the development of dementia in patients with prostate cancer.
This research work investigated the hypothesis that androgen deprivation therapy (ADT) can increase the risk of dementia in prostate cancer patients. Scientists from Stanford University School of Medicine looked at use of androgen deprivation drugs in comparison with the incidence rates of dementia among 9,272 patients with prostate cancer.
The team of investigators found out that exposure to androgen deprivation therapy raised the risk of dementia in prostate cancer patients. The data from this study indicate that prostate cancer patients treated with androgen deprivation therapy may be highly prone to suffer from dementia.